TTrialPathMatch Me to Trials
← Back to trials
RecruitingAlzheimer DiseaseAmyloidPlaque, Amyloid

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

Eligible age

18–85 yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Participants will enroll into either A1D-MC-AT01 (NCT07787182) or A1D-MC-AT02 (upcoming).

Sponsor: Eli Lilly and Company

You may qualify if…

  • ✓ Are between 18 and 45 years of age
  • ✓ Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²)
  • ✓ Are overtly healthy as determined by medical evaluation, including medical history, physical examination, and electrocardiograms (ECGs).
  • ✓ Are between 55-85 years of age
  • ✓ Have gradual and progressive changes in memory function, as reported by the participant or their study partner, for greater than or equal to (≥) 6 months at screening, as well as a clinical diagnosis of mild cognitive impairment due to AD or mild-to-moderate AD dementia as determined by the investigator or based on medical history.
  • ✓ Have Mini-Mental State Exam (MMSE) score ≥16
  • ✓ Have positive amyloid positron emission tomography (PET)
  • ✓ Have a reliable study partner who will provide written informed consent to participate and is in frequent contact with the participant. A second person may serve as backup.

You may not qualify if…

  • ✕ Have currently, or a history of, serious or unstable neurological or psychological disease (except for AD for participants in the AD cohorts).
  • ✕ Have currently, or a history of, significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological diseases.
  • ✕ Have currently, or a history of, allergies to monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone.
  • ✕ Have currently, or a history of, clinically significant multiple or severe drug allergies or severe posttreatment hypersensitivity reactions.
  • ✕ Have currently, or a history of cancer within the past 5 years except for some early skin cancers that have been resected with no evidence of metastatic disease for 3 years.
  • ✕ Have received any amyloid-targeting therapy (ATT), whether marketed or investigational; or have received active immunization against amyloid beta (Aβ).
  • ✕ Have received an active study intervention, within the last 30 days, in a clinical study involving an IMP.
  • ✕ Are pregnant or breastfeeding or intend to become pregnant or to breastfeed during the study;

Where it's recruiting

California

Anaheim · Irvine · Los Alamitos

Florida

Daytona Beach · Lady Lake · Maitland · Orlando …

Georgia

Decatur

Michigan

Farmington Hills

Source: ClinicalTrials.gov · NCT07787169 · last updated 2026-10-08

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Hea · TrialPath